U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H6Cl4O2S
Molecular Weight 356.052
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BITHIONOL

SMILES

OC1=C(Cl)C=C(Cl)C=C1SC2=CC(Cl)=CC(Cl)=C2O

InChI

InChIKey=JFIOVJDNOJYLKP-UHFFFAOYSA-N
InChI=1S/C12H6Cl4O2S/c13-5-1-7(15)11(17)9(3-5)19-10-4-6(14)2-8(16)12(10)18/h1-4,17-18H

HIDE SMILES / InChI

Molecular Formula C12H6Cl4O2S
Molecular Weight 356.052
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB04813 | https://goo.gl/7Qnwi7 | https://www.ncbi.nlm.nih.gov/pubmed/26961873 | https://www.ncbi.nlm.nih.gov/pubmed/5567745 | https://www.ncbi.nlm.nih.gov/pubmed/23990907

Bithionol is a synthetic sulfanediyl-bis-dichlorphenol), potent photosensitizer with the potential to cause serious skin disorders, formerly marketed as an active ingredient in various topical drug products. Bithionol has antibacterial and anthelmintic properties along with algaecide activity. Bithionol has been shown to be a potent inhibitor of soluble adenylyl cyclase (sAC, Adenylate cyclase type 10 ), an intracellular enzyme important in the catalysis of ATP to cAMP. Bithionol is the first known sAC inhibitor to act through the bicarbonate binding site via a mostly allosteric mechanism. Bithionol is used for treatment of tapeworm infections of dogs, cats, and poultry and for tapeworm and rumen fluke infections of sheep, horses, cattle, and goats.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
4.0 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Actamer

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
1 % 1 times / day single, topical
Studied dose
Dose: 1 %, 1 times / day
Route: topical
Route: single
Dose: 1 %, 1 times / day
Sources:
healthy, 22 years
Health Status: healthy
Age Group: 22 years
Sex: F
Sources:
Other AEs: Contact dermatitis...
Other AEs:
Contact dermatitis
Sources:
2.4 g 1 times / day multiple, oral
Studied dose
Dose: 2.4 g, 1 times / day
Route: oral
Route: multiple
Dose: 2.4 g, 1 times / day
Sources:
unhealthy, mean age 35 years
Health Status: unhealthy
Age Group: mean age 35 years
Sex: M+F
Sources:
Other AEs: Abdominal pain aggravated...
Other AEs:
Abdominal pain aggravated (37.5%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Contact dermatitis
1 % 1 times / day single, topical
Studied dose
Dose: 1 %, 1 times / day
Route: topical
Route: single
Dose: 1 %, 1 times / day
Sources:
healthy, 22 years
Health Status: healthy
Age Group: 22 years
Sex: F
Sources:
Abdominal pain aggravated 37.5%
2.4 g 1 times / day multiple, oral
Studied dose
Dose: 2.4 g, 1 times / day
Route: oral
Route: multiple
Dose: 2.4 g, 1 times / day
Sources:
unhealthy, mean age 35 years
Health Status: unhealthy
Age Group: mean age 35 years
Sex: M+F
Sources:
PubMed

PubMed

TitleDatePubMed
An improved thyroid hormone reporter assay to determine the thyroid hormone-like activity of amiodarone, bithionol, closantel and rafoxanide.
2012-01-05
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011-07-14
Determination of bithionol, bromophen, nitroxynil, oxyclozanide, and tribromsalan in milk with liquid chromatography coupled with tandem mass spectrometry.
2010-10-07
In vitro toxicity of bithionol and bithionol sulphoxide to Neoparamoeba spp., the causative agent of amoebic gill disease (AGD).
2010-09-17
Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action.
2010-05-01
A 20-year analysis of previous and emerging allergens that elicit photoallergic contact dermatitis.
2010-04
Endoscopic management of biliary fascioliasis: a case report.
2010-03-06
Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles.
2009-12-02
Molecular cloning, expression and characterization of a novel mouse SULT6 cytosolic sulfotransferase.
2009-09
Novel inhibitors complexed with glutamate dehydrogenase: allosteric regulation by control of protein dynamics.
2009-08-21
Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening.
2009-07-14
[Phosphatases of cestodes Bothriocephalus scorpii and influence of some anthelmintic preparations on activities of these enzymes].
2009-06-10
Diphyllobothriasis associated with eating raw pacific salmon.
2009-06
Evaluation of marked rise in fecal egg output after bithionol administration to horse and its application as a diagnostic marker for equine Anoplocephala perfoliata infection.
2009-05
Further development of bithionol therapy as a treatment for amoebic gill disease in Atlantic salmon, Salmo salar L.
2009-05
Combining chemical genomics screens in yeast to reveal spectrum of effects of chemical inhibition of sphingolipid biosynthesis.
2009-01-14
The old and new therapeutic approaches to the treatment of giardiasis: where are we?
2009
In Vitro Anthelmintic Activity of Baliospermum montanum Muell. Arg roots.
2008-01
Treatment of helminth co-infection in individuals with HIV-1: A systematic review of the literature.
2007-12-19
An evaluation of the effects of photoactivation of bithionol, amiodarone and chlorpromazine on human keratinocytes in vitro.
2007-10
Evaluation of bithionol as a bath treatment for amoebic gill disease caused by Neoparamoeba spp.
2007-03-31
Slack and Slick K(Na) channels regulate the accuracy of timing of auditory neurons.
2007-03-07
Induction of keratinocyte apoptosis by photosensitizing chemicals plus UVA.
2007-02
Indirect evidence of ectopic pancreatic fascioliasis in a human.
2006-10
Pharmacological activation and inhibition of Slack (Slo2.2) channels.
2006-09
Fasciola hepatica infection: clinical and computerized tomographic findings of ten patients.
2006-03
Kinetic, inhibition and structural studies on 3-oxoacyl-ACP reductase from Plasmodium falciparum, a key enzyme in fatty acid biosynthesis.
2006-01-15
Contractile activity and motility responses of the dog heartworm Dirofilaria immitis to classical anthelmintics and other compounds.
2005-11-25
Infection with Fasciola hepatica.
2005-11
Search of chemical scaffolds for novel antituberculosis agents.
2005-04
Acute toxicity to freshwater organisms of antiparasitic drugs for veterinary use.
2005-02
Fasciola hepatica infestation as a very rare cause of extrahepatic cholestasis.
2004-10-15
A native 13-kDa fatty acid binding protein from the liver fluke Fasciola hepatica.
2004-09-24
[Fascioliasis: diagnosis, epidemiology and treatment].
2004-05-07
Sonographic findings of hepatic lesions in human fascioliasis.
2003-09
Spectrum of cross-photosensitization in 18 consecutive patients with contact photoallergy to ketoprofen: associated photoallergies to non-benzophenone-containing molecules.
2003-03
[Antiparasitic treatments in pregnant women and in children in 2003].
2003
Paragonimiasis in Yongjia County, Zhejiang Province, China: clinical, parasitological and karyotypic studies on Paragonimus westermani.
2001-12
[Fasciola hepatica. study of a series of 37 patients].
2001-10
Hydrogen peroxide induced stress in human keratinocytes and its effect on bithionol toxicity.
2001-09-22
Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro.
1996-12
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.
1992-09
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Bithionol is given orally at a dose of 30 to 50 mg per kg of body weight on alternate days for ten to fifteen doses for the treatment of fascioliasis and paragonimiasis in adults and children.
After oral administration of single bithionol doses of 30 mg/kg body weight to healthy test persons (fasting, number not stated) no effects were observed, single oral doses of 50 mg/kg body weight caused diarrhoea and 150 mg/kg body weight prolonged diarrhoea, nausea and abdominal pains
Route of Administration: Oral
Cytotoxic effect of BT (Bithionol) was evaluated against a panel of ovarian cancer cell lines (A2780 & A2780-CDDP OVACAR-3, SKOV-3, IGROV-1, and IGROV-1CDDP). A 20 mM stock of BT was prepared in DMSO and all the working dilutions were prepared in DMEM media. Ovarian cancer cell lines (5 × 103 cells/well) were plated into 96-well flat bottom plates (Corning, Inc., Corning, NY) and incubated for overnight. Cells were treated with different concentrations of BT ranging from 0.178 μM to 400 μM and further incubated for 48 hrs or 72 hrs. At least 4–6 hrs before the end of treatment time, presto blue reagent was added and incubated for total of 48 or 72 hrs and fluorescence measured (540 nm excitation/590 nm emissions). DMSO concentration was corrected to 1% in all wells.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:34:42 GMT 2025
Edited
by admin
on Mon Mar 31 17:34:42 GMT 2025
Record UNII
AMT77LS62O
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BITHIN
Preferred Name English
BITHIONOL
HSDB   INN   JAN   MART.   MI   WHO-DD  
INN  
Official Name English
Bithionol [WHO-DD]
Common Name English
bithionol [INN]
Common Name English
BITHIONOL [HSDB]
Common Name English
BITHIONOL [MART.]
Common Name English
NSC-47129
Code English
BITHIONOL [MI]
Common Name English
LOROTHIDOL
Brand Name English
BITHIONOL [JAN]
Common Name English
2,2'-THIOBIS(4,6-DICHLOROPHENOL)
Systematic Name English
Classification Tree Code System Code
CFR 21 CFR 216.24
Created by admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
WHO-ATC P02BX01
Created by admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
WHO-VATC QD10AB01
Created by admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
EPA PESTICIDE CODE 64201
Created by admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
CFR 21 CFR 700.11
Created by admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
WHO-ATC D10AB01
Created by admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
NCI_THESAURUS C28394
Created by admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
WHO-VATC QP52AG07
Created by admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
Code System Code Type Description
NCI_THESAURUS
C77030
Created by admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
PRIMARY
EVMPD
SUB05857MIG
Created by admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
PRIMARY
DRUG BANK
DB04813
Created by admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
PRIMARY
ECHA (EC/EINECS)
202-565-0
Created by admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
PRIMARY
MERCK INDEX
m2577
Created by admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
PRIMARY Merck Index
INN
201
Created by admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
PRIMARY
MESH
D001735
Created by admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
PRIMARY
FDA UNII
AMT77LS62O
Created by admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
PRIMARY
HSDB
6380
Created by admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
PRIMARY
EPA CompTox
DTXSID9021342
Created by admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
PRIMARY
CAS
97-18-7
Created by admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
PRIMARY
SMS_ID
100000086322
Created by admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
PRIMARY
ChEMBL
CHEMBL290106
Created by admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
PRIMARY
WIKIPEDIA
BITHIONOL
Created by admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
PRIMARY
DRUG CENTRAL
3032
Created by admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
PRIMARY
ALANWOOD
bithionol
Created by admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
PRIMARY
NSC
47129
Created by admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
PRIMARY
PUBCHEM
2406
Created by admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
PRIMARY
CHEBI
3131
Created by admin on Mon Mar 31 17:34:42 GMT 2025 , Edited by admin on Mon Mar 31 17:34:42 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY